CO2017011535A2 - Composiciones de ácido obeticólico y métodos de uso - Google Patents
Composiciones de ácido obeticólico y métodos de usoInfo
- Publication number
- CO2017011535A2 CO2017011535A2 CONC2017/0011535A CO2017011535A CO2017011535A2 CO 2017011535 A2 CO2017011535 A2 CO 2017011535A2 CO 2017011535 A CO2017011535 A CO 2017011535A CO 2017011535 A2 CO2017011535 A2 CO 2017011535A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- compositions
- obetolic
- acid
- obetolic acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000002253 acid Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562153040P | 2015-04-27 | 2015-04-27 | |
| US201662317933P | 2016-04-04 | 2016-04-04 | |
| PCT/US2016/029369 WO2016176208A1 (en) | 2015-04-27 | 2016-04-26 | Compositions of obeticholic acid and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017011535A2 true CO2017011535A2 (es) | 2018-01-31 |
Family
ID=57198868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0011535A CO2017011535A2 (es) | 2015-04-27 | 2017-11-10 | Composiciones de ácido obeticólico y métodos de uso |
Country Status (25)
| Country | Link |
|---|---|
| US (8) | US10052337B2 (enExample) |
| EP (3) | EP3971199A1 (enExample) |
| JP (2) | JP6941057B2 (enExample) |
| KR (1) | KR20170140325A (enExample) |
| CN (1) | CN107531742A (enExample) |
| AU (2) | AU2016255045B2 (enExample) |
| BR (1) | BR112017023161A2 (enExample) |
| CA (1) | CA2983609C (enExample) |
| CL (1) | CL2017002727A1 (enExample) |
| CO (1) | CO2017011535A2 (enExample) |
| CR (1) | CR20170492A (enExample) |
| EA (1) | EA201792354A1 (enExample) |
| EC (1) | ECSP17078433A (enExample) |
| IL (2) | IL255269B (enExample) |
| MA (1) | MA41999A (enExample) |
| MX (1) | MX2017013805A (enExample) |
| NI (1) | NI201700128A (enExample) |
| PE (1) | PE20180690A1 (enExample) |
| PH (1) | PH12017501956A1 (enExample) |
| SG (2) | SG10202003110PA (enExample) |
| SV (1) | SV2017005555A (enExample) |
| TN (1) | TN2017000452A1 (enExample) |
| TW (1) | TWI723017B (enExample) |
| WO (1) | WO2016176208A1 (enExample) |
| ZA (1) | ZA201707981B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140441A2 (en) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| EP3712254A1 (en) | 2014-05-28 | 2020-09-23 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
| EP3207123A1 (en) | 2014-10-17 | 2017-08-23 | Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center | In vivo model of human small intestine using pluripotent stem cells and methods of making and using same |
| PE20180690A1 (es) * | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| JP6880000B2 (ja) * | 2016-03-31 | 2021-06-02 | インターセプト ファーマシューティカルズ， インコーポレイテッド | 有効成分の化学的安定性に優れたフィルムコーティング錠 |
| CA3020698A1 (en) * | 2016-04-13 | 2017-10-19 | Intercept Pharmaceuticals, Inc. | Methods of treating or preventing hepatocellular carcinoma |
| WO2017192997A1 (en) | 2016-05-05 | 2017-11-09 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
| AU2017290710A1 (en) * | 2016-06-29 | 2019-01-24 | Menlo Therapeutics Inc. | Use of neurokinin-1 antagonists to treat a variety of pruritic conditions |
| EP3534919A4 (en) * | 2016-11-04 | 2020-11-11 | Children's Hospital Medical Center | Liver organoid compositions and methods of making and using same |
| CN108072729A (zh) * | 2016-11-18 | 2018-05-25 | 华北制药集团新药研究开发有限责任公司 | 一种测定奥贝胆酸片溶出度的方法 |
| KR102807995B1 (ko) | 2016-12-05 | 2025-05-16 | 칠드런즈 호스피탈 메디칼 센터 | 결장 유사장기 및 이를 제조 및 사용하는 방법 |
| CN108614038B (zh) * | 2016-12-13 | 2022-05-17 | 亚宝药业集团股份有限公司 | 一种测定奥贝胆酸原料药有关物质的方法 |
| CN106645497A (zh) * | 2017-01-03 | 2017-05-10 | 山东省药学科学院 | 一种奥贝胆酸及其制剂中有关物质的检测方法 |
| TW201832768A (zh) * | 2017-03-07 | 2018-09-16 | 英特賽普醫藥品公司 | 治療癌症的方法 |
| US12281334B2 (en) | 2017-04-14 | 2025-04-22 | Children's Hospital Medical Center | Multi donor stem cell compositions and methods of making same |
| MX2020000873A (es) * | 2017-07-24 | 2020-07-22 | Intercept Pharmaceuticals Inc | Derivados de ácidos biliares marcados isotópicamente. |
| CA3077442A1 (en) | 2017-10-10 | 2019-04-18 | Children's Hospital Medical Center | Esophageal tissue and/or organoid compositions and methods of making same |
| WO2019106043A1 (en) * | 2017-11-29 | 2019-06-06 | Hexal Ag | Pharmaceutical composition comprising obeticholic acid |
| WO2019126626A1 (en) | 2017-12-21 | 2019-06-27 | Children's Hospital Medical Center | Digitalized human organoids and methods of using same |
| CN108572251B (zh) * | 2018-05-31 | 2020-01-17 | 中国科学院昆明动物研究所 | 肝硬化早期小分子标志物及其应用 |
| SG11202100533VA (en) | 2018-07-26 | 2021-02-25 | Childrens Hospital Med Ct | Hepato-biliary-pancreatic tissues and methods of making same |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| US11590161B2 (en) | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
| US11524029B2 (en) | 2018-08-13 | 2022-12-13 | Viscera Labs, Inc. | Therapeutic composition and methods |
| WO2020056158A1 (en) | 2018-09-12 | 2020-03-19 | Children's Hospital Medical Center | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
| EA202191299A1 (ru) * | 2018-11-08 | 2021-07-26 | Интерсепт Фармасьютикалз, Инк. | Способы применения обетихолевой кислоты |
| CN109432431B (zh) * | 2018-12-14 | 2020-06-30 | 中国药科大学 | 一种含有sumo抑制剂的组合物及应用 |
| CN109655571B (zh) * | 2019-01-08 | 2021-07-13 | 丽珠集团新北江制药股份有限公司 | 一种奥贝胆酸的高效液相色谱分析方法 |
| CN109620812B (zh) * | 2019-01-16 | 2023-07-21 | 浙江华海药业股份有限公司 | 一种奥贝胆酸组合物的制备方法 |
| CA3134536A1 (en) * | 2019-03-26 | 2020-10-01 | Intercept Pharmaceuticals, Inc. | Methods of diagnosis and treatment of liver diseases using obeticholic acid |
| WO2020198576A1 (en) * | 2019-03-28 | 2020-10-01 | The Board Of Trustees Of The University Of Illinois | Methods of modulating regulatory t cells |
| CA3141807A1 (en) | 2019-05-31 | 2020-12-03 | Children's Hospital Medical Center | Methods of generating and expanding hematopoietic stem cells |
| WO2021064575A1 (en) * | 2019-09-30 | 2021-04-08 | Novartis Ag | Treatment comprising the use of fxr agonists |
| EP4116710A4 (en) * | 2020-03-06 | 2024-04-24 | Mili Healthcare Trade DMCC, Limited Liability Company | APPLICATION OF A GROUP OF MARKERS FOR DIAGNOSIS AND TREATMENT MODIFICATION OF PRIMARY BILIARY CHOLANGITIS, PHARMACEUTICAL COMPOSITION, AND SOLID DOSAGE FORM FOR THE TREATMENT OF PRIMITIVE BILIARY CHOLANGITIS |
| CN115785183A (zh) * | 2020-04-23 | 2023-03-14 | 江西青峰药业有限公司 | 一种3α,7α-二羟基-6α-乙基-5β-胆烷-24-醛的制备方法及其应用 |
| WO2021231539A1 (en) * | 2020-05-13 | 2021-11-18 | Children's Hospital Medical Center | Alleviation of liver injury by activating the signaling pathway mediated by farnesoid x receptor |
| CN111690731B (zh) * | 2020-05-22 | 2021-09-28 | 河南大学 | Fxr激动剂在治疗肝性脑病中的应用 |
| CN111812264B (zh) * | 2020-07-09 | 2021-06-15 | 苏州旭辉检测有限公司 | 一种去氧胆酸类化合物的生物样品分析方法 |
| WO2022051321A1 (en) | 2020-09-03 | 2022-03-10 | Coherus Biosciences, Inc. | Fixed dose combinations of chs-131 and a fxr agonist |
| WO2022076683A1 (en) * | 2020-10-07 | 2022-04-14 | Intercept Pharmaceuticals, Inc. | Methods of treating coronaviral infection with obeticholic acid |
| CN113143950B (zh) * | 2021-05-17 | 2023-04-18 | 河北医科大学第二医院 | 一种治疗肝病的药物组合物及其应用 |
| WO2023147141A1 (en) * | 2022-01-28 | 2023-08-03 | Intercept Pharmaceuticals, Inc. | Combination therapy |
| WO2023181077A1 (en) * | 2022-03-24 | 2023-09-28 | Zenvision Pharma Llp | Stable liquid composition comprising obeticholic acid or salts thereof |
| US12343351B2 (en) | 2022-03-25 | 2025-07-01 | Rutgers, The State University Of New Jersey | Pulmonary function treatment |
| JP2025513289A (ja) * | 2022-04-21 | 2025-04-24 | インターセプト ファーマシューティカルズ， インコーポレイテッド | ファルネソイドｘ受容体アゴニストの使用 |
| WO2024043842A1 (en) * | 2022-08-22 | 2024-02-29 | Pharmactive Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients |
| WO2024104960A1 (en) | 2022-11-15 | 2024-05-23 | Synthon B.V. | Stable formulation comprising obeticholic acid |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| ZA876640B (en) * | 1986-09-26 | 1988-03-08 | Warner-Lambert Company | Treated lipid regulator |
| UA72207C2 (uk) | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
| US7078376B1 (en) | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| AU2002308295B2 (en) * | 2001-03-12 | 2007-08-23 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for FXR |
| EP2591806A1 (en) | 2001-06-14 | 2013-05-15 | Otsuka Pharmaceutical Co., Ltd. | Medicinal composition |
| US6933380B2 (en) | 2001-10-19 | 2005-08-23 | Yung-Zip Chemical Ind. Co., Ltd. | Excipients containing low residual solvent and method for producing the same |
| AU2003248786A1 (en) | 2002-07-03 | 2004-01-23 | Esperion Therapeutics, Inc. | Compositions comprising panthetine for the treatment of dyslipidemia |
| US20050101505A1 (en) * | 2003-11-06 | 2005-05-12 | Daniel Wood | Liquid laundry detergent composition having improved color-care properties |
| GB0402492D0 (en) | 2004-02-04 | 2004-03-10 | Pfizer Ltd | Pharmaceutically active compounds |
| GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| CA2614409C (en) * | 2005-07-07 | 2014-05-20 | Nanotherapeutics, Inc | Process for milling and preparing powders and compositions produced thereby |
| DE102007009242A1 (de) | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit magensaftresistenter Wirkstoff-Matix |
| JP2012520866A (ja) * | 2009-03-17 | 2012-09-10 | アプタリス・ファーマ・カナダ・インコーポレイテッド | 高用量のウルソデオキシコール酸で非アルコール性脂肪性肝炎を治療する方法 |
| JP5906181B2 (ja) | 2009-04-24 | 2016-04-20 | イシューティカ ピーティーワイ リミテッド | 商業的ナノ粒子及びマイクロ粒子粉末の生産方法 |
| CA2796494A1 (en) | 2010-04-20 | 2011-10-27 | Cipla Limited | Pharmaceutical composition |
| EP3336097B1 (en) * | 2012-06-19 | 2020-08-19 | Intercept Pharmaceuticals, Inc. | Preparation of the non-crystalline form of obeticholic acid |
| US9814733B2 (en) * | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| KR20150127599A (ko) | 2013-03-15 | 2015-11-17 | 모치다 세이야쿠 가부시키가이샤 | 비알코올성 지방간염을 치료하기 위한 조성물 및 방법 |
| PT3360881T (pt) | 2013-05-14 | 2021-02-19 | Intercept Pharmaceuticals Inc | Derivados de 11-hidroxilo substituídos em 6 de ácidos biliares e conjugados de aminoácidos dos mesmos como moduladores do recetor farnesoide x |
| EP3711762A1 (en) * | 2013-09-11 | 2020-09-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A farnesoid x receptor agonsits foruse and pharmaceutical compositions for the treatment of chronic hepatitis b virus infection |
| CN105801653B (zh) | 2014-12-30 | 2018-04-17 | 苏州晶云药物科技有限公司 | 奥贝胆酸的晶型a及其制备方法 |
| PE20180690A1 (es) * | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
-
2016
- 2016-04-24 PE PE2017002334A patent/PE20180690A1/es unknown
- 2016-04-26 CA CA2983609A patent/CA2983609C/en active Active
- 2016-04-26 TN TNP/2017/000452A patent/TN2017000452A1/en unknown
- 2016-04-26 EA EA201792354A patent/EA201792354A1/ru unknown
- 2016-04-26 US US15/139,138 patent/US10052337B2/en active Active
- 2016-04-26 MA MA041999A patent/MA41999A/fr unknown
- 2016-04-26 AU AU2016255045A patent/AU2016255045B2/en active Active
- 2016-04-26 EP EP21189718.6A patent/EP3971199A1/en not_active Withdrawn
- 2016-04-26 JP JP2017555791A patent/JP6941057B2/ja active Active
- 2016-04-26 IL IL255269A patent/IL255269B/en unknown
- 2016-04-26 EP EP16787000.5A patent/EP3288958A4/en not_active Withdrawn
- 2016-04-26 BR BR112017023161-1A patent/BR112017023161A2/pt not_active Application Discontinuation
- 2016-04-26 WO PCT/US2016/029369 patent/WO2016176208A1/en not_active Ceased
- 2016-04-26 CR CR20170492A patent/CR20170492A/es unknown
- 2016-04-26 EP EP24154375.0A patent/EP4371616A3/en active Pending
- 2016-04-26 SG SG10202003110PA patent/SG10202003110PA/en unknown
- 2016-04-26 CN CN201680023889.2A patent/CN107531742A/zh active Pending
- 2016-04-26 KR KR1020177033948A patent/KR20170140325A/ko not_active Withdrawn
- 2016-04-26 IL IL294575A patent/IL294575A/en unknown
- 2016-04-26 SG SG11201708606VA patent/SG11201708606VA/en unknown
- 2016-04-26 MX MX2017013805A patent/MX2017013805A/es unknown
- 2016-04-27 TW TW105113063A patent/TWI723017B/zh active
-
2017
- 2017-10-26 NI NI201700128A patent/NI201700128A/es unknown
- 2017-10-26 CL CL2017002727A patent/CL2017002727A1/es unknown
- 2017-10-26 PH PH12017501956A patent/PH12017501956A1/en unknown
- 2017-10-27 SV SV2017005555A patent/SV2017005555A/es unknown
- 2017-11-10 CO CONC2017/0011535A patent/CO2017011535A2/es unknown
- 2017-11-23 ZA ZA2017/07981A patent/ZA201707981B/en unknown
- 2017-11-24 EC ECIEPI201778433A patent/ECSP17078433A/es unknown
-
2018
- 2018-07-09 US US16/030,141 patent/US10646499B2/en active Active
-
2019
- 2019-01-15 US US16/248,512 patent/US10751349B2/en active Active
- 2019-10-08 US US16/596,741 patent/US20200046736A1/en not_active Abandoned
- 2019-10-08 US US16/596,216 patent/US20200046735A1/en not_active Abandoned
- 2019-10-09 US US16/597,412 patent/US20200054650A1/en not_active Abandoned
-
2020
- 2020-02-11 US US16/787,796 patent/US10758549B2/en active Active
- 2020-07-16 AU AU2020205315A patent/AU2020205315A1/en not_active Abandoned
-
2021
- 2021-09-03 JP JP2021143835A patent/JP2021183651A/ja active Pending
- 2021-12-06 US US17/542,923 patent/US20220133745A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017011535A2 (es) | Composiciones de ácido obeticólico y métodos de uso | |
| EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| MX2018007022A (es) | Metodos para tratar la enfermedad de huntington. | |
| MX389349B (es) | Derivados de ácido borónico y usos terapéuticos de los mismos. | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| CU20180001A7 (es) | Derivados de oxopiridina sustituidos y procesos para su preparación | |
| DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
| CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
| MX374191B (es) | Derivados de nucleósido sustituidos con 4´ -difluorometilo como inhibidores de la replicación de arn de la influenza. | |
| MX2020002123A (es) | Sales de ribociclib y formas en estado sólido de las mismas. | |
| MX2021000773A (es) | Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo. | |
| ECSP18074962A (es) | Derivados de aminotiazol útiles como agentes antivíricos | |
| CO2017002506A2 (es) | Nuevos activadores de la guanilato ciclasa soluble y su uso | |
| CL2019001053A1 (es) | Formulaciones farmacéuticas y métodos para prepararlas. | |
| MX384877B (es) | Composiciones de éster de colina de ácido lipoico y métodos de uso. | |
| MX2016012784A (es) | Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones. | |
| SV2017005412A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| CL2019002729A1 (es) | Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico. | |
| MX382116B (es) | Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas. | |
| CO2019008110A2 (es) | Activador de nrf2 | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| AR108616A1 (es) | Formulación combinada de tres compuestos antivirales | |
| EA201892157A1 (ru) | Фосфаплатиновые жидкие составы |